Substance Name: Ofatumumab [USAN:INN:BAN:JAN]
RN: 679818-59-8
UNII: M95KG522R0

An anti-CD20 MAb used as an antineoplastic agent; in phase 1-2 clinical trials.

An anti-CD20 MAb; in phase 1-2 clinical trials.

NCI: A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development. (NCI Thesaurus)

C6480-N10022-N1742-O2020-S44